1408. Deputy Marc MacSharry asked the Minister for Health further to Parliamentary Question No. 299 of 10 July 2019, if the HSE has considered a revised representation for the drug Tagrisso as a second line therapy for non-small cell lung cancer at recent drug group or senior leadership meetings; the dates such meetings took place or are scheduled to take place; the recommendation and decision made with regard to the reimbursement of the drug if a meeting took place; and if he will make a statement on the matter. [32804/19]

Summary

1408. Deputy Marc MacSharry asked the Minister for Health further to Parliamentary Question No. 299 of 10 July 2019, if the HSE has considered a revised representation for the drug Tagrisso as a second line therapy for non-small cell lung cancer at recent drug group or senior leadership meetings; the dates such meetings took place or are scheduled to take place; the recommendation and decision made with regard to the reimbursement of the drug if a meeting took place; and if he will make a statement on the matter. [32804/19]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Reimbursement

  xml · EN · 23 July 2019

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.